Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Abattis Bioceuticals Corp. (OTC: ATTBF).

Full DD Report for ATTBF

You must become a subscriber to view this report.


Recent News from (OTC: ATTBF)

The BAK Portfolio: Mary Jane Goes To Washington
Who Is Bay Area Kid? I am a 28-year-old Marine veteran currently enrolled in the MBA program at the University of Nevada, Las Vegas. I've been managing my own portfolio since 2010 and purchased a rental property in 2016. My long-term investment goal is to make enough money on the stock ...
Source: SeekingAlpha
Date: May, 09 2018 14:33
5 of Today's Biggest Marijuana Stock Losers - Friday, May 5th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Friday, May 5th including MYM Neutraceuticals Inc. (CSE:MYM) (OTC:MYMMF) and more... Abattis Bioceuticals Corp. (CSE:ATT) (OTC:ATTBF) Shares of Abattis Bioceuticals Corp. dropped 3.09% t...
Source: Daily Marijuana Observer
Date: May, 04 2018 17:14
Abattis to Commence Construction of Large-Scale Growing Facility on Gabriola Island
VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the " Company " or " Abattis ") (CSE:ATT) (OTC:ATTBF) is pleased to announce the engagement (the “ Engagement ”) of Ocean Pacific Contractors Ltd. (“ Ocean Pacific &#...
Source: GlobeNewswire
Date: May, 03 2018 11:56
Abattis Bioceuticals is Combining Cannabis Products and Blockchain Tech
NEW YORK, NY / ACCESSWIRE / May 1, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Abattis Bioceuticals Corp. (OTCQB: ATTBF), a life sciences an...
Source: ACCESSWIRE IA
Date: May, 01 2018 08:20
Abattis Completes Acquisition of Remaining Minority Interest in Gabriola Green Farms
Vancouver, British Columbia--(Newsfile Corp. - April 30, 2018) - Abattis Bioceuticals Corp. (the " Company " or " Abattis ") (CSE: ATT / OTC: ATTBF) is pleased to announce, further to its news release dated April 18, 2018, that it has completed its acquisition of the remaining 10% owner...
Source: Newsfile
Date: April, 30 2018 18:26
Abattis Enters into Agreement to Acquire Remaining Minority Interest in Gabriola Green Farms
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2018) - Abattis Bioceuticals Corp.  (CSE: ATT) (OTCQB: ATTBF) (the " Company " or " Abattis ") is pleased to announce that it has entered into a share purchase agreement to acquire (the " Acquisition ") the remaining 10% owner...
Source: Newsfile
Date: April, 18 2018 13:22
Abattis Announces Board Changes
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2018) - Abattis Bioceuticals Corp. (the " Company " or " Abattis ") (CSE: ATT) (OTCQB: ATTBF) is pleased to announce the addition of Cameron Paddock to the Board of Directors. Mr. Paddock will fill the vacancy left by the resignat...
Source: Newsfile
Date: April, 13 2018 14:07
5 of Today's Biggest Marijuana Stock Losers - Wednesday, April 4th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Wednesday, April 4th including Aurora Cannabis Inc. (TSX:ACB) (OTC:ACBFF) and more... Abattis Bioceuticals Corp. (CSE:ATT) (OTC:ATTBF) Shares of Abattis Bioceuticals Corp. dropped 12.99...
Source: Daily Marijuana Observer
Date: April, 04 2018 16:52
5 of Today's Biggest Marijuana Stock Losers - Thursday, March 29th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Thursday, March 29th including AXIM Biotechnologies Inc. (OTC:AXIM) and more... Abattis Bioceuticals Corp. (CSE:ATT) (OTC:ATTBF) Shares of Abattis Bioceuticals Corp. dropped 6.07% toda...
Source: Daily Marijuana Observer
Date: March, 29 2018 16:51
Abattis Announces $8 Million Financing and Successfully Closes First Tranche of Financing
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, March 27, 2018 (GLOBE NEWSWIRE) --   Abattis Bioceuticals Corp. (the " Company " or " Abattis ") (CSE:ATT) (OTC:ATTBF) is pleased to announce that...
Source: GlobeNewswire
Date: March, 27 2018 07:00

 


About Abattis Bioceuticals Corp. (OTC: ATTBF)

Logo for Abattis Bioceuticals Corp. (OTC: ATTBF)

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio similar compounds, patented equipment and consulting services to medicinal marijuana markets in North America.

 

Contact Information

 

 

Current Management

  • Robert Abenante / CEO, President
  • Rene David / COO
  • David Whitney / CFO
  • Christina Boddy / Corporate Secretary
  • Shuang Xie / CTO
  • Michael Bluestein / Securities Counsel
  • Robert Abenante /
  • Rene David /
  • Peter Gordon /
  • James Irving / Independent Director, Audit Committee Member
  • William Panenka / Independent Director

Current Share Structure

  • Market Cap: $62,612,714 - 03/15/2018
  • Issue and Outstanding: 291,221,927 - 03/01/2018
  • Float: 91,134,125 - 09/06/2016

 


Recent Filings from (OTC: ATTBF)

Management Discussion and Analysis - Q1 MD&A
Filing Type: Management Discussion and Analysis - Q1 MD&AFiling Source: OTC Markets
Filing Date: February, 28 2018
Interim Financial Report - Q1 Interim Financial Statements
Filing Type: Interim Financial Report - Q1 Interim Financial StatementsFiling Source: OTC Markets
Filing Date: February, 28 2018
Management Discussion and Analysis - Annual MD&A - September 30, 2017
Filing Type: Management Discussion and Analysis - Annual MD&A - September 30, 2017Filing Source: OTC Markets
Filing Date: January, 31 2018
Annual Report - Audited Annual Financial Statements - September 30, 2017
Filing Type: Annual Report - Audited Annual Financial Statements - September 30, 2017Filing Source: OTC Markets
Filing Date: January, 31 2018
Management Discussion and Analysis - Abattis Q3 2017 Interim MD&A
Filing Type: Management Discussion and Analysis - Abattis Q3 2017 Interim MD&AFiling Source: OTC Markets
Filing Date: October, 19 2017
Interim Financial Report - Abattis Q3 2017 Interim Financial Statements
Filing Type: Interim Financial Report - Abattis Q3 2017 Interim Financial StatementsFiling Source: OTC Markets
Filing Date: October, 19 2017
Management Discussion and Analysis - Abattis Q2 2017 Amended Interim MD&A
Filing Type: Management Discussion and Analysis - Abattis Q2 2017 Amended Interim MD&AFiling Source: OTC Markets
Filing Date: October, 19 2017
Interim Financial Report - Abattis Q2 2017 Amended Interim Financial Statements
Filing Type: Interim Financial Report - Abattis Q2 2017 Amended Interim Financial StatementsFiling Source: OTC Markets
Filing Date: October, 19 2017
Management Discussion and Analysis - Abattis - Q2 2017 - Interim MD&A
Filing Type: Management Discussion and Analysis - Abattis - Q2 2017 - Interim MD&AFiling Source: OTC Markets
Filing Date: June, 12 2017
Quarterly Report - Abattis - Q2 2017 - Interim Financial Statements
Filing Type: Quarterly Report - Abattis - Q2 2017 - Interim Financial StatementsFiling Source: OTC Markets
Filing Date: June, 12 2017

 

 


Daily Technical Chart for (OTC: ATTBF)

Daily Technical Chart for (OTC: ATTBF)


Stay tuned for daily updates and more on (OTC: ATTBF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ATTBF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATTBF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of ATTBF and does not buy, sell, or trade any shares of ATTBF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/